Skip to main content
. 2022 Mar 28;60(5):54. doi: 10.3892/ijo.2022.5344

Figure 2.

Figure 2

Combined treatment of adavosertib and ricolinostat enhances cell death only in TP53-KO A549 cells. (A) TP53 KO in A549 cells was confirmed by western blotting. Expression of p53, phospho-p53, and p21 was assessed after doxorubicin (DOX) (1 µM) treatment for 24 h. β-actin was used as a loading control. Relative band intensity of p-p53/p53 was calculated and is summarized in the right panel. (B) TP53-WT and TP53-KO A549 cells were treated with Adv in combination with RCS for up to 48 h. Cells were monitored using IncuCyte live cell imaging system, and dead cell number was assessed by PI staining. Dose-dependent and time-dependent cell death numbers are shown. The synergistic effect on cell death in combination treatment was assessed and is summarized at the right. Representative data of three independent experiments are shown. n=3, bar, mean ± SD. Adv, adavosertib; RCS, ricolinostat.